Cargando…
Study on Hydroxyurea Response in Hemoglobinopathies Patients Using Genetic Markers and Liquid Erythroid Cultures
Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies. Hydroxyurea (HU) is the only inducer approved for the treatment of these diseases able to stimulate HbF production but patients’ response is highly variable indicating the utility of the identifi...
Autores principales: | Sclafani, Serena, Pecoraro, Alice, Agrigento, Veronica, Troia, Antonio, Di Maggio, Rosario, Sacco, Massimiliano, Maggio, Aurelio, D’Alcamo, Elena, Di Marzo, Rosalba |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178820/ https://www.ncbi.nlm.nih.gov/pubmed/28053695 http://dx.doi.org/10.4081/hr.2016.6678 |
Ejemplares similares
Ejemplares similares
-
Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
por: Di Maggio, Rosario, et al.
Publicado: (2018) -
P-075: HYDROXYUREA: EFFECTS ON TREATMENT OF CHILDREN WITH HEMOGLOBINOPATHY SC
por: A., CAMPOS, et al.
Publicado: (2022) -
Incidence of cancer and related deaths in hemoglobinopathies: A follow‐up of 4631 patients between 1970 and 2021
por: Origa, Raffaella, et al.
Publicado: (2022) -
Pure Erythroid Leukemia in a Sickle Cell Patient Treated with Hydroxyurea
por: Yadav, Dhiraj Kumar, et al.
Publicado: (2020) -
Nitric Oxide Synthase Dependency in Hydroxyurea Inhibition of Erythroid Progenitor Growth
por: Subotički, Tijana, et al.
Publicado: (2021)